{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T06:08:24Z","timestamp":1770962904560,"version":"3.50.1"},"reference-count":47,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2016,9,22]],"date-time":"2016-09-22T00:00:00Z","timestamp":1474502400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0162903","type":"journal-article","created":{"date-parts":[[2016,9,22]],"date-time":"2016-09-22T14:11:46Z","timestamp":1474553506000},"page":"e0162903","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":43,"title":["Metabolic Effects Associated with ICS in Patients with COPD and Comorbid Type 2 Diabetes: A Historical Matched Cohort Study"],"prefix":"10.1371","volume":"11","author":[{"given":"David B.","family":"Price","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3890-7201","authenticated-orcid":true,"given":"Richard","family":"Russell","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9153-4662","authenticated-orcid":true,"given":"Rafael","family":"Mares","sequence":"additional","affiliation":[]},{"given":"Anne","family":"Burden","sequence":"additional","affiliation":[]},{"given":"Derek","family":"Skinner","sequence":"additional","affiliation":[]},{"given":"Helga","family":"Mikkelsen","sequence":"additional","affiliation":[]},{"given":"Cherlyn","family":"Ding","sequence":"additional","affiliation":[]},{"given":"Richard","family":"Brice","sequence":"additional","affiliation":[]},{"given":"Niels H.","family":"Chavannes","sequence":"additional","affiliation":[]},{"given":"Janwillem W. H.","family":"Kocks","sequence":"additional","affiliation":[]},{"given":"Jeffrey W.","family":"Stephens","sequence":"additional","affiliation":[]},{"given":"John","family":"Haughney","sequence":"additional","affiliation":[]}],"member":"340","published-online":{"date-parts":[[2016,9,22]]},"reference":[{"issue":"9859","key":"ref1","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","article-title":"Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"R Lozano","year":"2012","journal-title":"Lancet"},{"issue":"9859","key":"ref2","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1016\/S0140-6736(12)61729-2","article-title":"Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990\u20132010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"T Vos","year":"2012","journal-title":"Lancet"},{"key":"ref3","unstructured":"NICE. Chronic obstructive pulmonary disease. Management of chronic obstructive pulmonary disease in adults in primary and secondary care (partial update)2010."},{"key":"ref4","unstructured":"Global Initiative for Chronic Obstructive Lung DG. Global strategy for the diagnosis, management and preention of chronic obstructive pulmonary disease (updated 2014). Global Initiative for Chronic Obstructive Lung Disease, Inc.; 2014. p. 102."},{"key":"ref5","unstructured":"(NICE) NIfHaCE. Chronic obstructive pulmonary disease 2010 [updated November 2010; cited 2015 01\/10\/2015]. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/cks.nice.org.uk\/chronic-obstructive-pulmonary-disease\" xlink:type=\"simple\">http:\/\/cks.nice.org.uk\/chronic-obstructive-pulmonary-disease<\/ext-link>."},{"issue":"11","key":"ref6","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.amjmed.2010.06.019","article-title":"Inhaled corticosteroids and the risks of diabetes onset and progression","volume":"123","author":"S Suissa","year":"2010","journal-title":"Am J Med"},{"issue":"10","key":"ref7","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.2337\/dc12-2197","article-title":"Comorbid diabetes and COPD: impact of corticosteroid use on diabetes complications","volume":"36","author":"GE Caughey","year":"2013","journal-title":"Diabetes Care"},{"issue":"5","key":"ref8","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s40265-014-0202-z","article-title":"Meta-review: adverse effects of inhaled corticosteroids relevant to older patients","volume":"74","author":"K Mattishent","year":"2014","journal-title":"Drugs"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2174\/1874306401408010059","article-title":"Systemic effects of inhaled corticosteroids: an overview","volume":"8","author":"D Pandya","year":"2014","journal-title":"Open Respir Med J"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"f3306","DOI":"10.1136\/bmj.f3306","article-title":"Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting beta2 agonist: observational matched cohort study (PATHOS)","volume":"346","author":"C Janson","year":"2013","journal-title":"BMJ"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/1475-2840-11-132","article-title":"Chronic obstructive pulmonary disease and glucose metabolism: a bitter sweet symphony","volume":"11","author":"AE Mirrakhimov","year":"2012","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"ref12","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.amjmed.2008.09.048","article-title":"The association of inhaled corticosteroid use with serum glucose concentration in a large cohort","volume":"122","author":"CG Slatore","year":"2009","journal-title":"Am J Med"},{"issue":"6","key":"ref13","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s00592-014-0584-0","article-title":"Diabetes mellitus among outpatients with COPD attending a university hospital","volume":"51","author":"P Rogliani","year":"2014","journal-title":"Acta Diabetol"},{"issue":"9823","key":"ref14","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(11)60968-9","article-title":"Chronic obstructive pulmonary disease","volume":"379","author":"M Decramer","year":"2012","journal-title":"Lancet"},{"issue":"12","key":"ref15","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1136\/thx.2007.086827","article-title":"Obesity and the lung: 5. Obesity and COPD","volume":"63","author":"FM Franssen","year":"2008","journal-title":"Thorax"},{"issue":"6","key":"ref16","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1183\/09031936.01.00213701","article-title":"Guidelines versus clinical practice in the treatment of chronic obstructive pulmonary disease","volume":"18","author":"N Roche","year":"2001","journal-title":"European Respiratory Journal"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1471-2466-14-56","article-title":"Real-life use of fluticasone propionate\/salmeterol in patients with chronic obstructive pulmonary disease: a French observational study","volume":"14","author":"N Roche","year":"2014","journal-title":"BMC Pulm Med"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2147\/COPD.S62750","article-title":"Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns","volume":"9","author":"D Price","year":"2014","journal-title":"International journal of chronic obstructive pulmonary disease"},{"key":"ref19","unstructured":"Clinical Practice Research Datalink. [cited 2013 October 17]. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.cprd.com\/home\/\" xlink:type=\"simple\">http:\/\/www.cprd.com\/home\/<\/ext-link>."},{"key":"ref20","unstructured":"Optimum Patient Care (OPC). [cited 2015 June 27]. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.optimumpatientcare.org\/\" xlink:type=\"simple\">http:\/\/www.optimumpatientcare.org\/<\/ext-link>."},{"key":"ref21","unstructured":"(BMA) TBMA, Employers N, England N. 2015\/16 General Medical Services (GMS) contract Quality and Outcomes Framework (QOF). Guidance for GMS contract 2015\/162015. p. 162."},{"key":"ref22","unstructured":"(HSCIC) HSCIC. Quality and Outomes Framework (QOF) [cited 2015 08\/10\/2015]. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.hscic.gov.uk\/qof\" xlink:type=\"simple\">http:\/\/www.hscic.gov.uk\/qof<\/ext-link>."},{"issue":"1","key":"ref23","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1136\/bmjqs-2012-001033","article-title":"Recorded quality of primary care for patients with diabetes in England before and after the introduction of a financial incentive scheme: a longitudinal observational study","volume":"22","author":"E Kontopantelis","year":"2013","journal-title":"BMJ Qual Saf"},{"key":"ref24","unstructured":"Organization WH. Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus 2011 Contract No.: WHO\/NMH\/CHP\/CPM\/11.1."},{"issue":"9","key":"ref25","doi-asserted-by":"crossref","first-page":"e24278","DOI":"10.1371\/journal.pone.0024278","article-title":"A longitudinal study examining adherence to guidelines in diabetes care according to different definitions of adequacy and timeliness","volume":"6","author":"G Sidorenkov","year":"2011","journal-title":"PLoS One"},{"issue":"1\u20132","key":"ref26","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3121\/cmr.2009.824","article-title":"The effect of an inhaled corticosteroid on glucose control in type 2 diabetes","volume":"7","author":"JL Faul","year":"2009","journal-title":"Clin Med Res"},{"key":"ref27","unstructured":"Society BT, Network SIG, Scotland HI. British Guideline on the Management of Asthma. A national clinical guideline2008."},{"issue":"6","key":"ref28","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1183\/09031936.00166410","article-title":"What the pulmonary specialist should know about the new inhalation therapies","volume":"37","author":"BL Laube","year":"2011","journal-title":"The European respiratory journal: official journal of the European Society for Clinical Respiratory Physiology"},{"issue":"6","key":"ref29","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1136\/dtb.2008.05.0013","article-title":"Switching to CFC-free beclometasone for asthma","volume":"46","year":"2008","journal-title":"Drug Ther Bull"},{"issue":"4","key":"ref30","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1183\/09031936.00065013","article-title":"The distribution of COPD in UK general practice using the new GOLD classification","volume":"43","author":"J Haughney","year":"2014","journal-title":"Eur Respir J"},{"issue":"2","key":"ref31","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1177\/1932296815599551","article-title":"Economic Value of Improved Accuracy for Self-Monitoring of Blood Glucose Devices for Type 1 Diabetes in Canada","volume":"10","author":"RB McQueen","year":"2016","journal-title":"J Diabetes Sci Technol"},{"key":"ref32","unstructured":"Optimum Patient Care Research Database (OPCRD) 2015 [17\/08\/2015]. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/optimumpatientcare.org\/our-database\/\" xlink:type=\"simple\">http:\/\/optimumpatientcare.org\/our-database\/<\/ext-link>."},{"issue":"6","key":"ref33","first-page":"461","article-title":"Evidence of a threshold value of glycated hemoglobin to improve the course of renal function in type 2 diabetes with typical diabetic glomerulopathy","volume":"14","author":"E Brocco","year":"2001","journal-title":"J Nephrol"},{"issue":"6","key":"ref34","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.2337\/dc11-9998","article-title":"Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus","volume":"34","author":"DB Sacks","year":"2011","journal-title":"Diabetes Care"},{"issue":"7","key":"ref35","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.rmed.2012.03.008","article-title":"How far is real life from COPD therapy guidelines? An Italian observational study","volume":"106","author":"A Corrado","year":"2012","journal-title":"Respiratory medicine"},{"issue":"6","key":"ref36","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1183\/09031936.01.00213701","article-title":"Guidelines versus clinical practice in the treatment of chronic obstructive pulmonary disease","volume":"18","author":"N Roche","year":"2001","journal-title":"The European respiratory journal: official journal of the European Society for Clinical Respiratory Physiology"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2174\/1874306401408010101","article-title":"Effect of inhaled corticosteroids on glycemic status","volume":"8","author":"F Egbuonu","year":"2014","journal-title":"Open Respir Med J"},{"issue":"8","key":"ref38","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMoa063070","article-title":"Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease","volume":"356","author":"PM Calverley","year":"2007","journal-title":"The New England journal of medicine"},{"issue":"1","key":"ref39","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1164\/rccm.200707-973OC","article-title":"The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol\/fluticasone propionate or tiotropium bromide","volume":"177","author":"JA Wedzicha","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"ref40","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1164\/rccm.200602-244OC","article-title":"Impact of salmeterol\/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease","volume":"175","author":"P Kardos","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"ref41","article-title":"Optimizing Treatment of Elderly COPD Patients: What Role for Inhaled Corticosteroids?","author":"AP Rossi","year":"2015","journal-title":"Drugs Aging"},{"issue":"12","key":"ref42","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1517\/14656566.2015.1067682","article-title":"A re-evaluation of the role of inhaled corticosteroids in the management of patients with chronic obstructive pulmonary disease","volume":"16","author":"A D'Urzo","year":"2015","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"ref43","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1164\/rccm.200611-1630OC","article-title":"Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia","volume":"176","author":"P Ernst","year":"2007","journal-title":"American journal of respiratory and critical care medicine"},{"issue":"11","key":"ref44","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1136\/thoraxjnl-2012-202872","article-title":"Inhaled corticosteroids in COPD and the risk of serious pneumonia","volume":"68","author":"S Suissa","year":"2013","journal-title":"Thorax"},{"issue":"5","key":"ref45","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1183\/09031936.04.00121404","article-title":"Impact of preventing exacerbations on deterioration of health status in COPD","volume":"23","author":"S Spencer","year":"2004","journal-title":"Eur Respir J"},{"issue":"1","key":"ref46","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1183\/09031936.03.00013303","article-title":"Inhaled Steroids in Obstructive Lung Disease in Europe study i. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations","volume":"21","author":"PW Jones","year":"2003","journal-title":"Eur Respir J"},{"issue":"1","key":"ref47","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1183\/09031936.03.00031402","article-title":"Efficacy and safety of budesonide\/formoterol in the management of chronic obstructive pulmonary disease","volume":"21","author":"W Szafranski","year":"2003","journal-title":"Eur Respir J"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0162903","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T18:22:20Z","timestamp":1568398940000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0162903"}},"subtitle":[],"editor":[{"given":"Qing","family":"Lu","sequence":"first","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2016,9,22]]},"references-count":47,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2016,9,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0162903","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,22]]}}}